美银-新产业(300832):2026年一季度中国试剂业务复苏,重申买入但下调目标价-New Industries Biomedical Engineering(A)China reagent business recovers in 1Q26;reiterate Buy but lower PO-20260428【9页】

发表回复

后才能评论